TransCode Therapeutics Net Income

The latest net income for RNAZ is $-63B as of June 2026. That compares with $-14B in the prior-year period — down 334.4% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside TransCode Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNAZ's net income moved from $-14B to $-63B — a 334.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TransCode Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, RNAZ currently prints $-63B for net income, while the sector average sits near $16B. That is roughly 493.8% below the sector mean. Large gaps often invite a closer look at TransCode Therapeutics's growth, margins, and balance sheet.

A net income figure of $-63B for RNAZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting RNAZ's net income ($-63B), review year-over-year change from $-14B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.